All manufacturers Aburaihan Alchemia Pharma Alpha Pharma Anhui Anke Biotechnology Arcas Nutrition Balkan Pharmaceuticals Bayer Bio-Peptide Biochem Bioniche Pharma Bioreaktor Biosira BM Pharmaceuticals Body Research British Dispensary British Dragon Canada Peptides Centurion Laboratories Cooper Desma Diamond Dynamic Labs Eifelfango Euro PharmLabs Excel Pharma Galenika GeneScience Genesis Hilma Biocare Iran Hormone Jelfa Jinan Pharmaceuticals Kohoh Pharma Kubera Pharma Lilly Magnus Pharmaceuticals Malay Tiger MultiPharm Nordex Norma Nouveaux Novo Nordisk Novosarm Onyx Organon Pfizer Pharmacom Phoenix Primus Ray Lab QPharma Royal Pharma Sandoz Sci Pharma Tech Shree Venkatesh SIS Labs SP Labarotories Spectrum Pharma Sport Pharma Swiss Remedies Titan Vermodje West Pharm Zenit Pharma ZPHC
After the Kefauver Harris Amendment was passed in 1962, the . FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol.  In 1965, the FDA pressured CIBA to further document its legitimate medical uses, and re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism .  After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the .